Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease
Biogen Inc. (Nasdaq: BIIB), Beckman Coulter, Inc. and Fujirebio announced a collaboration to potentially identify and develop blood-based biomarkers for tau pathology in the brain and to potentially clinically advance and potentially commercialize new tests for tau pathology in Alzheimer’s disease (AD). The development of tau-specific blood-based biomarkers that can measure a patient’s tau burden could provide critical insights into the underlying pathological processes of AD and may help advance the development of a new generation of therapies impacting tau pathology.
Through this collaboration, the companies will work to identify new blood-based biomarkers and advance known blood-based biomarkers for tau pathology in AD. The collaboration aims to develop and clinically advance new tools that measure brain tau pathology to potentially stratify patients or monitor treatment response in AD clinical trials. The collaboration has the potential to advance tau-specific blood-based biomarkers and diagnostic tools that could be used not only in clinical trials, but also in clinical practice to enable adoption of future therapies impacting tau pathology.
“Stratifying and monitoring patients for tau pathology is a growing need for the next generation of Alzheimer's therapies, such as our pipeline of investigational tau-targeting therapies, including tau-directed ASO” said Jane Grogan, Ph.D., Head of Research at Biogen. “Through this collaboration, we plan to leverage our deep scientific expertise in the development and use of biomarkers, combined with our partners’ capabilities in diagnostics, to potentially accelerate the development timeline for blood-based diagnostics that can measure a patient’s levels of tau pathology.”
“Collaborative efforts between Biogen, Beckman Coulter and Fujirebio combine the strength of leading edge biomarker development with innovative potential treatments focused on the tauopathy aspect of neurodegeneration, driving us closer to effective solutions," said Kathleen Orland, Senior Vice President, General Manager, Chemistry, and Immunoassay for Beckman Coulter Diagnostics. “Ensuring high quality neurological tests are broadly available through our global installed-base of analyzers, this collaboration with Biogen and Fujirebio underscores our commitment to working with leaders in neurodegenerative disease areas to bring fully automated, high throughput, blood-based Alzheimer's disease testing to the millions of patients who suffer from dementia worldwide.”
“Blood-based biomarkers for tau pathology could advance the development and implementation of disease-modifying therapies for neurodegenerative disorders such as AD,” said Monte Wiltse, President & CEO of Fujirebio Diagnostics, Inc. “This partnership will further help us accelerate our efforts to develop novel neurodegenerative disease diagnostics and deliver them to laboratories and clinicians around the world via our global diagnostics partners, addressing the unmet medical need for blood-based biomarkers.”
Under the terms of the collaboration, Biogen will provide Alzheimer's clinical study data and expertise in biomarker research to prioritize markers for tau pathology. Fujirebio and Beckman Coulter will be responsible for providing diagnostic development, manufacturing and commercialization.
About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.
We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Facebook, LinkedIn, X, YouTube.
About Beckman Coulter. Inc.
A global leader in advanced diagnostics, Beckman Coulter has challenged convention to elevate the diagnostic laboratory’s role in improving patient health for more than 80 years. Our mission is to Relentlessly Reimagine Healthcare, One Diagnosis at a Time – and we do this by applying the power of science, technology and the passion and creativity of our teams. Our diagnostic solutions are used in complex clinical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. We exist to deliver smarter, faster diagnostic solutions that move the needle forward from what’s now to what’s next. We do this by accelerating care with an extensive clinical menu, scalable lab automation technologies, insightful clinical informatics, and lab performance services. Headquartered in Brea, Calif., Beckman Coulter has more than 11,000 global team members. 2024-13330.
Follow and connect with Beckman Coulter via LinkedIn, X, and Facebook
About Fujirebio
Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality in vitro diagnostics (IVD) testing. It has more than 50 years’ accumulated experience in the conception, development, production, and worldwide commercialization of robust IVD products. Fujirebio supplies new technology and novel diagnostic markers to the global Diagnostics industry through material supply, contract development and manufacturing.
Fujirebio was the first company to develop and market CSF biomarkers under the Innogenetics brand over 25 years ago. Fujirebio remains the only company with such a comprehensive line-up of manual and fully automated neurodegenerative disease assays and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier and more complete neurodegenerative diagnostic tools. More information can be found at www.fujirebio.com/alzheimer.
Biogen Safe Harbor
This press release contains forward-looking statements, relating to: our strategy and plans; potential of, and expectations for, our commercial business and pipeline programs; capital allocation and investment strategy; clinical development programs, clinical trials, and data readouts and presentations; the potential for blood based AD biomarker tests; regulatory discussions, submissions, filings, and approvals; the potential benefits, safety, and efficacy of our and our collaboration with Beckman Coulter Diagnostics and Fujirebio;. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “potential,” “possible,” “prospect,” “will,” “would,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our dependence on sales from our products; uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; failure to compete effectively; failure to successfully execute or realize the anticipated benefits of our strategic and growth initiatives; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks associated with current and potential future healthcare reforms; risks related to commercialization of biosimilars; failure to obtain, protect, and enforce our data, intellectual property, and other proprietary rights and the risks and uncertainties relating to intellectual property claims and challenges; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; risks relating to technology failures or breaches; problems with our manufacturing processes; risks relating to management, personnel and other organizational changes, including attracting and retaining personnel; failure to comply with legal and regulatory requirements; the risks of doing business internationally, including currency exchange rate fluctuations; risks relating to investment in our manufacturing capacity; risks relating to the distribution and sale by third parties of counterfeit or unfit versions of our products; risks relating to the use of social media and artificial intelligence based software for our business; results of operations, and financial condition; fluctuations in our operating results; risks related to investment in properties; risks relating to access to capital and credit markets; risks related to indebtedness; the market, interest, and credit risks associated with our investment portfolio; risks relating to share repurchase programs; change in control provisions in certain of our collaboration agreements; fluctuations in our effective tax rate; environmental risks; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission.
These statements speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240730216833/en/
Contacts
MEDIA CONTACT(S):
Biogen
Jack Cox
+ 1 781 464 3260
public.affairs@biogen.com
Beckman Coulter Diagnostics
Jeff Tarmy
+ 1 617 467 7537
jtarmy@beckman.com
H.U. Group Holdings/Fujirebio
Kazumi Kobayashi
+ 81 3 6279 0884
pr@hugp.com
INVESTOR CONTACT(S):
Biogen
Chuck Triano
+1 781 464 2442
IR@biogen.com
H.U. Group Holdings/Fujirebio
Hisashi Yamakawa
+ 81 3 6279 0926
ir@hugp.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ProAmpac Advances Recyclable Flexible and Fibre-Based Packaging at Packaging Innovations 202511.2.2025 22:03:00 CET | Press Release
ProAmpac, a leader in flexible packaging and material science, will exhibit its latest recyclable and high-performance packaging solutions at Packaging Innovations 2025, taking place February 12–13 at the NEC Birmingham. Visitors can find ProAmpac at Booth L80, where the company will highlight its latest advancements in fibre-based packaging, recyclable films, and food-to-go solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250211772764/en/ Hot Cabinet (Photo: Business Wire) "At ProAmpac, we are proud to lead the way in developing sustainable packaging solutions that meet the needs of both consumers and the environment. Our advancements in fibre-based and recyclable flexible packaging demonstrate our commitment to innovation and a circular economy," said Kristy Paulin, executive vice president of global marketing for ProAmpac. "We invite attendees to visit us at Booth L80 to explore these innovations firsthand and di
Lattice to Showcase Cutting-Edge Programmable Solutions at embedded world 202511.2.2025 22:00:00 CET | Press Release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced its exhibition plan for embedded world 2025. The latest Lattice technology will be on full display throughout the tradeshow with expert-led conference sessions, in addition to a demo-filled booth display focused on Edge AI, connectivity, video, and security. Joined by a strong lineup of innovation partners, Lattice will showcase its latest advancements in FPGA solutions that enable engineers to innovate and accelerate their designs for Automotive, Industrial, and Security applications at the Edge. Who: Lattice Semiconductor What / When: Lattice Booth and Demo Showcase: March 11 – 13, Hall 4, Booth #528 Conference Sessions Mar 11 at 2:15 – 2:45 p.m. GMT+1 Session 6.1 (MIPI for Embedded Vision): “Machine Vision Processing of Event based Sensor with MIPI Interface on FPGAs” Mar 12 at 11 – 11:30 a.m. GMT+1 Session 1.13 (Cellular IoT): “Green FPGA: The Role of FPGA in Waveform Agnostics Radio Unit (RU)
Mary Kay Inspires Future Innovators: Young Women in STEM ‘Blend’ Beauty and Science11.2.2025 21:59:00 CET | Press Release
Mary Kay Inc., a global leader in science, innovation, and furthering young women’s education marked the 10th anniversary of the International Day of Women and Girls in Science on February 11 with an exploratory event aimed to inspire the next generation of female STEM leaders. According to UNESCO, “Women make up only 35% of students enrolled in STEM-related fields of study in higher education" (UNESCO, 2020). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250211969602/en/ Students from Lewisville High School – Harmon Campus (Texas, U.S.A.) putting their knowledge to the test by creating their own Mary Kay® Unlimited Lip Gloss at Mary Kay's global Richard R. Rogers Manufacturing and Research & Development Center (Photo Credit: Mary Kay Inc.) Thirty students from Lewisville High School – Harmon Campus arrived at Mary Kay’s Richard R. Rogers Manufacturing / R&D Center (R3) in Lewisville, TX, where they were greeted with an ins
Bureau Veritas Recognized for Leading Effort Against Climate Change, Entering the CDP “A List”11.2.2025 17:45:00 CET | Press Release
Bureau Veritas is proud to announce that it has been included in the A list for Climate reporting in 2024 by the CDP. In a record-breaking year with 24.800+ corporations, representing more than two-thirds of the global market capitalization, Bureau Veritas ranks amongst the top-tier performers worldwide. Such recognition from one of the most prestigious climate corporate assessments underlines the Group’s strong engagement and commitment to tackling global warming. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250211550878/en/ Hinda Gharbi, CEO Bureau Veritas (Photo: Business Wire) This accolade recognizes Bureau Veritas’ concrete actions to mitigate climate risk, accelerate energy transition and push towards a decarbonized economy as part of the Group’s LEAP | 28 strategy which puts sustainability at its core. The company has focused on reducing the carbon footprint of its business activities and is embarking on its 83,000
Armis, the Cyber Exposure Management & Security Company, Appoints Alex Mosher as President11.2.2025 17:00:00 CET | Press Release
Armis, the Cyber Exposure Management & Security company, today announced, from its Accelerate Conference in Mexico, the promotion of Alex Mosher to President of Armis with immediate effect. As part of its five year business strategy, Armis is committed to listing publicly and building a multi-generational cybersecurity company. In his new role as President, Mosher will lead Armis’ unified go-to-market functions and continue to drive change at speed as the company scales to support its rapid growth. “Alex has demonstrated his ability to repeatedly deliver and win since he came to Armis. He has been a tremendous colleague, partner and leader. He has a unique ability of bringing differing GTM teams together and leading them to shared success,” said Yevgeny Dibrov, Co-founder and CEO, Armis. “Alex has successfully delivered time and time again, as our former Chief Revenue Officer, and I now look forward to him being even more successful in this ambitious new expanded role, as President.” A
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom